Meeting
2022 ASCO Annual Meeting
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
Presenter
Naoki Furuya, MD, PhD
Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
031190066
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9110)
DOI
10.1200/JCO.2022.40.16_suppl.9110
Abstract #
9110
Poster Bd #
96
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
A biomarker study of atezolizumab (atezo) + bevacizumab (bev) + carboplatin (carbo) + paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043.
Speaker: Satoshi Watanabe, MD, PhD
Speaker: Anthony Cmelak, MD
Videos & Slides
2024 ASCO Annual Meeting
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.
Speaker: Helena Alexandra Yu, MD
Videos & Slides
2022 ASCO Annual Meeting
Afatinib (Afa) + bevacizumab (Bev) versus afatinib alone as first-line treatment of patients with EGFR-mutated advanced non-squamous NSCLC: Primary analysis of the multicenter, randomized, phase II study—AfaBev-CS study.
Speaker: Nobuhisa Ishikawa, MD, PhD